Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.55M+57.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$63M+4.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Biogen logo
BiogenBIIB
uniQure logo
uniQureQURE
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX

Other financials

Income statement

See full
Revenue--100%
Operating income-$47.3M-77.0%
Net income-$46.6M-73.5%
EPS (diluted)-$0.13-44.4%

Balance sheet

See full
Cash & equivalents$455.4M+45.6%
Total debt$56.7M-5.1%
Total equity$387.3M+55.7%
Total assets$470.4M+41.1%

Cash flow

See full
Operating cash flow-$40.4M-100%
CapEx$24.0K-93.7%
Free cash flow-$40.4M-100%

Valuation

See full
Market cap$1.83B+154%
Enterprise value$1.43B+205%
P/S333.7×+245×

Profitability

See full
Operating margin-2,792.3%-9,679pp
Net margin-2,728%-9,858pp
FCF margin-2,417%-8,925pp

Returns & leverage

See full
Return on equity-47.1%-4.0pp
Debt / equity0.1×-0.1×
Current ratio17.8×+5.3×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344610
Line itemJune 30,2026December 31,2025
Restricted cash1642,315
Property, plant and equipment, net2,4126,736
Operating lease right-of-use assets6,3179,439
Other non-current assets106183
Total assets$470,433$343,320
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$9,164$6,275

Item 1. Financial Statements.

FAQ

What is Taysha Gene Therapies, Inc.'s deferred tax assets and other non-current assets?
Taysha Gene Therapies, Inc. (TSHA) reported deferred tax assets and other non-current assets of $106K in Q2 2026.
How has Taysha Gene Therapies, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Taysha Gene Therapies, Inc.'s deferred tax assets and other non-current assets decreased by 43.0% year-over-year, from $186K to $106K.
What is the long-term trend for Taysha Gene Therapies, Inc.'s deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s deferred tax assets and other non-current assets has grown at a -36.2% compound annual growth rate (CAGR), from $1.11M to $183K.
What does deferred tax assets and other non-current assets mean?
Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.

Ask your AI about Taysha Gene Therapies, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude